trimetrexate has been researched along with Uterine Neoplasms in 2 studies
Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.
Uterine Neoplasms: Tumors or cancer of the UTERUS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study was conducted to determine the objective response of trimetrexate in patients with advanced or recurrent leiomyosarcoma of the uterus." | 9.10 | Trimetrexate in the treatment of recurrent or advanced leiomyosarcoma of the uterus: a phase II study of the Gynecologic Oncology Group. ( Blessing, JA; Smith, HO; Vaccarello, L, 2002) |
| "This study was conducted to determine the objective response of trimetrexate in patients with advanced or recurrent leiomyosarcoma of the uterus." | 5.10 | Trimetrexate in the treatment of recurrent or advanced leiomyosarcoma of the uterus: a phase II study of the Gynecologic Oncology Group. ( Blessing, JA; Smith, HO; Vaccarello, L, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Smith, HO | 1 |
| Blessing, JA | 2 |
| Vaccarello, L | 1 |
| Fowler, JM | 1 |
| Burger, RA | 1 |
| Malfetano, JH | 1 |
2 trials available for trimetrexate and Uterine Neoplasms
| Article | Year |
|---|---|
Trimetrexate in the treatment of recurrent or advanced leiomyosarcoma of the uterus: a phase II study of the Gynecologic Oncology Group.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Drug Administration Schedule; Fe | 2002 |
Phase II evaluation of oral trimetrexate in mixed mesodermal tumors of the uterus: a gynecologic oncology group study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Drug Administration | 2002 |